Literature DB >> 16027318

Recalcitrant cutaneous sarcoidosis responding to infliximab.

Michael P Heffernan, Milan J Anadkat.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16027318     DOI: 10.1001/archderm.141.7.910

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  7 in total

Review 1.  The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy.

Authors:  Julie H Wu; Sotonye Imadojemu; Avrom S Caplan
Journal:  Am J Clin Dermatol       Date:  2022-05-18       Impact factor: 6.233

Review 2.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Disfiguring annular sarcoidosis improved by adalimumab.

Authors:  C A Kaiser; A Cozzio; G F L Hofbauer; J Kamarashev; L E French; A A Navarini
Journal:  Case Rep Dermatol       Date:  2011-05-17

Review 4.  Adaptive immune responses in primary cutaneous sarcoidosis.

Authors:  Matteo Bordignon; Paola Rottoli; Carlo Agostini; Mauro Alaibac
Journal:  Clin Dev Immunol       Date:  2011-03-30

5.  Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Authors:  José Luis Callejas-Rubio; Lourdes López-Pérez; Norberto Ortego-Centeno
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

6.  A case series of refractory cutaneous sarcoidosis successfully treated with infliximab.

Authors:  Papapit Tuchinda; Matthew Bremmer; Anthony A Gaspari
Journal:  Dermatol Ther (Heidelb)       Date:  2012-07-26

Review 7.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.